Blog | HemaCare

HemaCare to supply pre-screened PBMCs to facilitate engraftment of human cells for Charles River’s new NCG mouse humanization kit.

Feb 20, 2018 10:21:00 AM / by Nancy Andon, MSc

ncg-mouse-kit-logos (002).jpgCharles River’s Humanized Mouse Model Accelerates Research by Incorporating HemaCare PBMCs

Last week, FierceBiotech featured the new mouse “humanization” kit from Charles River that will incorporate pre-selected human peripheral blood mononuclear cells (PBMCs) from HemaCare. [1] So-called “humanized” mice are genetically engineered so that they lack significant components of their immune system. These immunodeficient mice are carefully engrafted with human PBMCs, allowing them to develop human immune cells, thereby replicating an environment that more closely resembles a human immune system.  The mice are commonly used to model the human immune response to various cancer treatments (including cell and gene therapy), as well as treatments for disease states related to the immune system. 

Announced earlier this month, HemaCare is strategically partnering with Charles River Laboratories, a well-known early stage contract research organization, to facilitate research on the human immune system by developing a more efficient method for working with humanized mouse models. [2] The NCG/PBMC Select Humanization Kit from Charles River offers several advances over conventional mouse humanization kits.  The NCG mice that the kit is based on are more fully immunocompromised than other commonly used mouse models. The NCG mouse genome incorporates CRISPR/Cas 9 technology which was originally developed at Nanjing University in China. The genome contains several engineered mutations that allow the mouse’s immune system to quickly form human immune cells following engraftment with PBMCs. The new mouse model also solves another challenge common to the humanization process. Engraftment of PBMC cells can differ with each human donor, making immune responses frustratingly variable. To avoid this issue, HemaCare will provide Charles River with PBMCs from donors preselected for their high engraftment rates and low immunogenicity.  The two companies anticipate that their combined strategy will make mouse humanization easier, faster, and more reliable.

Iva Morse, Charles River's CSO of Global Research Models and Services explains that the most important consideration for her company in choosing to partner with HemaCare is the fact that they have one of the largest donor databases in the world. Because of the company’s long-standing relationship with their donors, past donors may be recalled for repeat collection, which enhances HemaCare’s ability to provide high value PBMCs.

Humanized mouse models are an essential tool for immunological research. This new humanized mouse kit stands to save researchers in both time and resources normally spent on characterizing PBMC donor cells. HemaCare are proud to be part of this collaboration that will ultimately accelerate drug discovery and development. Learn more about HemaCare’s best-in-class cells.


[1] Liu A. Charles River taps HemaCare’s PBMC for humanized mouse models. FierceBiotech. Feb. 2018.

[2] HemaCare and Charles River Laboratories Announce Strategic Partnership to Accelerate Drug Discovery and Development. HemaCare Corporation. Feb. 2018.

Topics: PBMCs

Nancy Andon, MSc

Written by Nancy Andon, MSc

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts